Overview

To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
Primary: To compare the gastroprotective effects of a once-daily dose of PA 325 combination tablet combining 325 mg pH sensitive aspirin and 20 mg immediate release omeprazole versus a once-daily dose of 325 mg enteric coated aspirin utilizing Lanza scores from endoscopy findings in normal healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
POZEN
Treatments:
Aspirin
Omeprazole